[Wadden STEP 3, JAMA 2021] STEP 5 Trial (Nature Medicine 2022) Long-term data: patients maintained an average 15.2% weight loss over 2 years of continuous semaglutide use, with sustained metabolic improvements including reduced HbA1c, blood pressure, and waist circumference
They have helped me get on track, lose weight and be accountable for what Im eating and being healthy
TMAO y microbiota: por qu aparece en la literatura El TMAO (trimetilamina N-xido) es un metabolito que puede formarse a partir de precursores dietticos por la accin de la microbiota
After a fall, many women move less out of fear
As the first and only dual-activating GIP and GLP-1 obesity treatment, ZEPBOUND, Eli Lilly weight loss medication, addresses a key factor contributing to excess weight by curbing appetite and reducing food intake
10.1016/j.biopha.2020.110426 51 ZmysowskiA.SzterkA